The question of how much lab space a life sciences company actually needs — versus how much office it can live with — sits at the intersection of science strategy, real estate economics, and operational risk. Answering it wrong in either direction is expensive: over-indexed on wet lab drives shell costs and mechanical complexity that cannot be easily reversed, while over-indexed on office leaves bench-critical staff competing for scarce hood time and slows program timelines. Getting the split right requires a disciplined methodology that moves from scientific programming through facility-planning, financial modeling, and finally lease structure.
Understanding the Nature of the Space Types
Lab space and office space are not simply different rooms in the same building. They are fundamentally different infrastructure investments that carry different costs per square foot to build, different ongoing operating loads, and different flexibility profiles when a program pivots or a team grows.
Wet lab space — including BSL-2 research environments, chemistry suites, and analytical instrument rooms — requires structural slabs capable of carrying vibration-sensitive equipment, dedicated exhaust systems for fume hoods, above-standard ceiling heights to route mechanical and plumbing services, and emergency power for cold storage. Those requirements mean wet lab shell-and-core costs run materially higher than conventional office in every major life sciences market, though the precise premium varies by geography, building vintage, and landlord investment.
Office space in a life sciences building is still not standard commercial office. Occupant density in bio-pharma and medical device companies tends to run higher than a law firm or financial services tenant, conferencing demands are heavy, and collaboration zones need acoustic treatment because cross-functional team conversation is a daily operating rhythm. That said, the structural and mechanical requirements are orders of magnitude less than the adjacent lab, which is exactly why the ratio between the two has such a direct line to overall project cost.
Understanding those differences at the outset prevents teams from inadvertently designing a building program that requires lab-grade mechanical systems in spaces that will function as open-plan offices. That mistake happens more often than facility-planning professionals acknowledge, usually because the initial programming brief was drafted before the science leadership team had finalized which assays would run in-house versus at a contract research organization.
Starting With the Scientific Program, Not the Headcount
The most common error in a lab-to-office ratio exercise is to start with headcount — to count the people on the team, apply an industry benchmark like 150 to 250 square feet per person, and work backward to a building size. That method produces a total square footage number, but it does not produce a defensible lab-to-office split because headcount does not tell you which assays run, how many simultaneous experiments are staged, or how many fume hoods must be live at peak utilization.
The right starting point is a scientific program statement. The science leadership team — typically the VP of Research, the head of each functional group, and the facilities lead — should produce a written inventory of every laboratory function the company will perform in-house over the planning horizon. That horizon is usually three to five years, long enough to capture one drug program cycle but not so long that the inventory becomes speculative science fiction.
Each function in the inventory gets a space type assignment: wet lab, dry lab (computational biology, bioinformatics), analytical lab (mass spectrometry, NMR, imaging), cell culture suite, cold room, chemical storage, or support space. Functions that require hood time are counted separately from functions that require bench space without exhaust. That distinction alone can swing the ratio by ten to fifteen percentage points in a hypothetical planning scenario.
Once every function is assigned a space type, the team calculates the number of work positions per function, the equipment footprint, and the support space allocation — corridors, write-up areas, shared equipment rooms. That bottom-up build produces a gross lab square footage requirement that is grounded in science, not in a benchmark someone read in a trade publication.
Defining the Office Program With Equal Rigor
The office portion of the program gets underweighted in most life sciences facility-planning exercises because it is perceived as the simpler side of the equation. In practice, the office program drives significant cost and lease negotiation leverage because it is the most flexible part of the footprint.
A rigorous office program starts by identifying every non-lab function: executive leadership, business development, finance, legal, regulatory affairs, medical affairs, human resources, IT, and project management. Each function is modeled at its current headcount, its projected headcount at the end of the planning horizon, and its peak simultaneous occupancy — the number of people from that group who will actually be in the building on the busiest day of the week.
Peak simultaneous occupancy is the planning variable that most teams skip. If a regulatory affairs team of twenty people travels four days a week for agency meetings and advisory boards, their peak in-building occupancy may be eight people on a Friday. Designing twelve assigned workstations for that group and allocating proportional conference room, amenity, and support space inflates the office footprint without producing any operational benefit.
The output of the office program is a space allocation table that shows each function's workstations, collaborative areas, support space, and total net square footage, summed to a total office net area. That figure is then grossed up using an efficiency factor — the ratio of net assignable area to gross building area — which typically runs between sixty and seventy-five percent in life sciences buildings depending on corridor configuration and core placement.
Applying the Right Ratio Framework
With both sides of the program grounded in real requirements, the lab-to-office ratio can be calculated from the bottom up rather than assumed from the top down. For early-stage companies running a single program in a single modality, the ratio commonly skews toward lab — sometimes sixty to seventy percent lab, thirty to forty percent office — because the team is small and the bench work is intensive. For later-stage companies managing multiple programs across modalities and carrying a larger commercial and administrative organization, the ratio often moves toward a fifty-fifty split or even flips.
Those figures are illustrative, not prescriptive. The ratio that matters is the one derived from your scientific program and your office program, not from an industry average. Industry averages are useful as a sanity check — if your bottom-up analysis produces a ninety percent lab program for a company with sixty administrative staff, something is wrong with either the science inventory or the office program assumptions.
One framework that helps validate the ratio is to run the lab program through a utilization stress test. For each lab type, calculate the ratio of peak simultaneous users to the number of work positions designed. If the analytical lab has eight instrument positions but only three people who run instruments on any given day, the lab program for that function is oversized. If the cell culture suite has four biosafety cabinets and six scientists who all need cabinet time during a Monday morning cell passage, the suite is undersized. The stress test surfaces both conditions before they are locked into a lease.
Modeling the Financial Implications of the Split
The lab-to-office ratio is not just a programming question. It is a financial decision with long-term lease implications. Tenant improvement allowances in life sciences leases are structured differently from standard office leases because landlords know that lab build-outs require significantly more capital to deliver. Understanding how the ratio affects the total cost of occupancy is a prerequisite for any lease negotiation.
As a starting point, model the total project cost — tenant improvements, furniture, equipment, and moving — for two or three alternative ratio scenarios. In a hypothetical scenario, consider a sixty-forty lab-to-office split versus a fifty-fifty split for a fifty-thousand square foot building. The lab-heavy scenario may carry a meaningfully higher construction cost per square foot, which affects how much tenant improvement allowance the company needs to request and how that amortization interacts with effective rent over the lease term. Those trade-offs need to be visible before the team negotiates a letter of intent.
Lease net present value analysis is the right tool for comparing ratio scenarios when the financial implications span multiple years. An NPV model discounts all future rent obligations and tenant improvement repayment against an appropriate discount rate, allowing the team to see which scenario produces the lower total occupancy cost in present-value terms.
Identifying the Right Building and Market
Once the program and the preliminary ratio are established, the site selection process can begin with real specificity. Life sciences tenants have building requirements that standard office searches do not — floor-to-floor heights, slab-to-slab clearance for mechanical service, structural load capacity, power availability, emergency generator provisions, and proximity to research institutions or other anchor tenants in an established cluster. Without the program grounded first, a site tour is just a walkthrough.
The building search should start with a criteria weighting exercise. Assign weights to the requirements that are non-negotiable — floor-to-floor height, power, loading dock access — and distinguish them from requirements that are strongly preferred but negotiable, such as amenity quality, proximity to public transit, or the landlord's track record in life sciences build-outs. A weighted scoring matrix allows the team to evaluate multiple properties on the same basis and document the rationale for advancing or eliminating each option. That documentation becomes critical when a CFO or board asks why the team chose one building over another.
Structuring Flexibility Into the Lease
One of the most consequential decisions in a life sciences facility-planning process is how much flexibility to build into the lease to accommodate program change. Lab programs change — a Phase 2 failure eliminates an entire modality; a partnership with a contract research organization absorbs work that was previously done in-house; a new platform technology requires a different lab type than the original program assumed. A lease that does not account for that volatility can trap a company in space that no longer fits the science.
Flexibility provisions worth negotiating include expansion options on adjacent space, rights of first offer on contiguous floors, sublease rights with reasonable landlord consent conditions, and contraction options that allow the tenant to give back a defined portion of the premises at a predetermined point in the lease term. Each of those provisions has a cost — landlords price flexibility because it limits their own optionality — but the cost must be weighed against the scenario where the company needs to pivot and finds itself locked into a building program that cannot accommodate the new direction.
The lab-to-office split itself should be approached with built-in flexibility. Rather than designing every square foot to a fixed assignment, life sciences tenants can designate a percentage of the total footprint as convertible space — areas built to lab-ready shell specifications (reinforced slab, adequate ceiling height, rough plumbing) that can be finished as either lab or office depending on where the program lands. That approach carries a higher initial construction cost for the convertible zone but provides real optionality that a pure office build-out does not.
Managing the Phased Buildout
Most life sciences tenants do not occupy a full building from day one. The more common pattern is a phased buildout in which the initial premises covers current needs and optioned space is held for future activation. Planning the phase line — the physical demarcation between occupied and optioned space — requires coordination between the architect, the contractor, the landlord, and the facilities team well before construction begins.
The phase line affects mechanical design more than any other system. HVAC in a life sciences building is not easily partitioned after the fact because lab exhaust systems are often designed as building-wide systems rather than zone-by-zone systems. If the phase line is drawn carelessly, the company may be paying operating expenses for mechanical infrastructure that serves unoccupied space, or the landlord may require a minimum system configuration that runs at overcapacity relative to the initial occupied footprint.
Phased fit-out also creates sequencing dependencies that affect move-in timelines. If Phase 1 occupancy requires the loading dock to be operational but the dock serves a building wing that is not part of Phase 1 construction, the sequencing problem needs to be identified and resolved in the construction schedule before the lease is executed, not after. Facilities teams that have navigated phased life sciences build-outs successfully tend to run a detailed critical path analysis of the first occupancy milestone and work backward from that date to identify every sequencing dependency.
Coordinating the Real Estate and Scientific Teams
The lab-to-office planning process fails most often not because of a technical error in the programming or the financial model, but because the real estate team and the scientific team operate on separate tracks and do not exchange information at the right points in the timeline.
Real estate decisions in a life sciences company — which building, which configuration, what lease terms — have historically been made by the CFO or the head of corporate development with input from an outside adviser, while the science leadership team was consulted only on the specific lab requirements they submitted in a brief. That siloed model produces a building program that satisfies the stated requirements but misses the unstated ones: the head of chemistry who assumed there would be a cold room on every floor, the director of analytical sciences who plans to bring a major instrument in-house within eighteen months, the clinical team that needs a GMP suite that nobody mentioned in the original brief.
A structured decision process brings the two teams together at defined milestones: at the initial program statement, at the ratio finalization, at the building shortlist review, at the lease term negotiation, and at the construction document review. That discipline sounds bureaucratic, but it is what prevents a forty-thousand square foot fit-out from becoming a fifty-thousand square foot project because requirements kept expanding without a corresponding revision to the financial model.
Running the Full Methodology: A Synthesis
The question of how to plan the lab-to-office split for a life sciences company resolves to a sequence of eight decisions, each of which must be grounded in real requirements before the next one is made. The scientific program comes first; the office program second; the ratio is derived from both; the financial implications of the ratio are modeled before the building search begins; the building search uses a structured scoring process; the lease is negotiated with explicit flexibility provisions; the phased buildout is planned with mechanical and sequencing constraints in view; and the two teams — real estate and scientific — are coordinated at defined milestones throughout.
Shortcuts anywhere in that sequence produce predictable failures. Skipping the scientific program and defaulting to an industry benchmark produces a ratio that may not support the actual work. Skipping the financial modeling produces a lease negotiation that lacks leverage. Skipping the milestone coordination produces a fit-out full of late-stage change orders.
The methodology described here is not a checklist that can be executed once and filed. It is a living process that the team returns to as the science evolves, as the lease timeline advances, and as the market for life sciences space changes.
ADVANTAGE AI LLC, a Delaware limited liability company, operates the platform under published terms at advantaico.com.
The best life sciences facility-planning outcomes share a common characteristic: the team treated the building decision as a science decision and the science decision as a real estate decision, holding both in view simultaneously throughout the process. When the lab bench count drives the lease term and the lease term constrains the program horizon, the people managing the real estate and the people managing the science need to be reading from the same page — literally and operationally.
About Advantai
Advantai is a commercial real estate intelligence and operations platform operated by ADVANTAGE AI LLC, a Delaware limited liability company. It connects client relationships, property research, documents and financial decisions in one workspace for commercial real estate teams — advisers and brokerage teams, occupier and facility teams, and portfolio teams. The platform covers CRM and origination, requirements and site selection, Property X-Ray (an interactive 3D building workspace), financial modeling and comparison, document intelligence, transactions and diligence, client collaboration, and portfolio strategy with deadline tracking. The optional Super Agent upgrade adds specialist, source-backed research and automated scenario analysis.
Get Started with Advantai
Ready to see your next move clearly? Go to advantaico.com, click Request a demo and tell us about your next project. Prefer to start with a single project? Visit advantaico.com/getting-started to plan your first one.